By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Aventis Pharmaceuticals, Inc. 

(A subsidiary of Aventis S.A.)
300 Somerset Corporate Boulevard
Bridgewater  New Jersey  08807  U.S.A.
Phone: 800-981-2491 Fax:

Hoechst Marion Roussel and Rhone-Poulenc Rorer have adopted the name Aventis Pharmaceuticals to create: A new world class leader in the pharmaceutical industry.

From the start, Aventis Pharmaceuticals will have the resources to become a leader in today's highly competitive pharmaceutical industry: one of the world's largest research and development budgets, commercial strengths in all of the world's major markets, experienced international management and an outstanding workforce. This 13 billion euro giant ranks among the leaders worldwide in prescription drug sales, has a sales force with proven effectiveness, and a robust market presence around the world.

Our mission is to generate a continuous flow of significant therapies to support the competitiveness and growth of Aventis by:

  • Fostering a creative and open environment that leverages our diversity and in which teamwork and communication flourish

  • Realizing employees potential to contribute to human health and the quality of life

  • Generating and transferring knowledge through projects and partnerships

  • Shortening or improving the identification, validation and approval of products by using cutting-edge science, technologies, quality processes and data

    What most pharmaceutical companies call Research and Development will look much different at Aventis Pharmaceuticals. The company is pursuing a “new paradigm” to organize all of the global functions- from discovery of new molecules, through preclinical and clinical studies and on to regulatory efforts into a single organization called Drug Innovation and Approval.

    Located in the heart of the world's largest and fastest-growing healthcare market, the Aventis Pharmaceutical Global Drug Development Center (GDDC) in Bridgewater, New Jersey provides a strategic center for key global activities and teams.

    The GDDC concept is designed to enhance information sharing, responsiveness, resource optimization, regulatory strategies and outsourcing flexibility. Specifically, the Bridgewater GDDC enhances Aventis Pharmaceuticals’ operations through:

  • Global coherence and consistency and rapid global late-stage development

  • Integrated planning and rapid decision making

  • Close interaction among cross-functional global teams (DI&A, Global Marketing and Corporate Development)

  • Key presence in the strategically important U.S. market

    DI&A Discovery Research includes (in the U.S):
    Immunology Platform
    Respiratory Diseases
    Rheumatoid Arthritis
    CNS/neuropsychiatric and neuroinflammatory disorders
    Lead Generation
    High Throughput Screening
    Medicinal Chemistry
    Physical Chemistry
    Automated Synthesis

    DI&A Global Functions include:
    Product Realization (Clinical Research)
    Lead Optimization
    Drug Regulatory Affairs

    Strategic Brands
    The products of Aventis Pharma improve the lives of millions of patients around the world. Among the currently marketed brands, Aventis Pharma's five major growth drivers already are contributing to improving financial performance.

    Click to view strong growth drivers

    Last Updated 5/8/00

    Key Statistics

    Ownership: Public

    Web Site: Aventis Pharmaceuticals, Inc.
    Symbol: AVE

  • Industry


    Primogenix Incorporated 

    Axys Pharma 

    Cell Genesys, Inc. (Acquired by BioSante Pharmaceuticals, Inc.)  Licensing agreement for gene-activated erythropoietin (EPO)

    Celera Corporation  Aventis is investigating the use of Cathepsin S inhibitors in a number of therapeutic areas related to inflammation and autoimmune disease.

    Phylos, Inc.  In April 1998, Phylos entered into a $27 million collaboration with Hoechst Research & Technology GmbH (now Aventis) to develop the Company's core PROfusion™ technology. Under the terms of the agreement, Aventis provides Phylos with research funding for a minimum of five years, in exchange for certain rights to the technology and specific products resulting from the collaboration.

    Company News
    Aventis Pharmaceuticals, Inc. (AVE) to Pay U.S. $95.5 Million to Settle False Claims Act Allegations 5/28/2009 10:16:17 AM
    Cortria Corporation Appoints Dennis H. Giesing, Ph.D., Former Worldwide Head of Lead Optimization at Aventis Pharmaceuticals, Inc. (AVE), as Head of Research and Development 12/9/2008 9:33:51 AM
    Out at Work: Diversity in the Pharmaceutical and Biotechnology Industries 6/29/2007 7:29:19 PM
    Amgen (AMGN) Wins Transkaryotic Therapies, Inc. (TKTX) Appeal 8/3/2006 1:18:45 PM
    Barr Laboratories (BRL) Says Court Denies Preliminary Injunction To Halt Generic Allegra(R) Sales 1/27/2006 4:19:31 PM
    Organon Enters Into Distribution Agreement For Anzemet(R) 12/5/2005 11:29:53 AM
    Inyx, Inc. Secures $46 Million In Available Non-Dilutive, Asset-Based Financing From Westernbank Puerto Rico10/19/2005 5:13:11 PM
    Inyx, Inc. Completes Acquisition Of Aventis Pharmaceuticals Puerto Rico Inc.10/19/2005 5:13:11 PM
    Inyx, Inc. Announces Expanded Relationship With NovaDel Pharma (NVD)10/19/2005 5:12:57 PM
    IMPAX Laboratories, Inc. (IPXL) Files Motion To Intervene As Defendant In Litigation Related To Generic Allegra-D10/19/2005 5:12:52 PM